COVID-19 and Guillain–Barré Syndrome

On April 17, 2020, the online New England Journal of Medicine published the correspondence Guillain–Barré Syndrome Associated with SARS-CoV-2.  The paper was authored by a team of Italian physicians and describes a previously unreported potential association between COVID-19 and Guillain–Barré Syndrome, an autoimmune disease associated with ascending paresthesia and paralysis of the lower extremities.

The team reported that, of an estimated 1000 to 1200 patients with COVID-19 admitted to three hospitals in Northern Italy from February 28 through March 21, 2020, five patients developed Guillain–Barré syndrome within 10 days of the onset of COVID-19 symptoms.  In four of these patients, lower-limb weakness and paresthesia were among the first symptoms noted.

Although viral infections have long been considered a possible trigger for Guillain–Barré syndrome, this is believed to be the first report indicating a potential association between the SARS-CoV-2, the virus that causes of COVID-19, and Guillain–Barré syndrome.  Other viruses associated with Guillain–Barré Syndrome include Zika virus, Epstein–Barr virus, cytomegalovirus, human immunodeficiency virus (HIV), influenza virus and the coronavirus responsible for Middle East Respiratory Syndrome (MERS).

On a personal note, I would like to take this opportunity to wish all of you the best of luck during these trying times.  These are truly dark days, but they will pass.

To the heroes among us who have put their own health at risk by treating patients with COVID-19, thank you for your good work, your bravery and your courage.  You make us all very proud and exceedingly grateful.

.


A request from the author:
Have any of your patients who have taken NeuRemedy experienced any benefits in addition to improvement in their neuropathic symptoms? If so, I would like to know. Please contact me at rhm123@gmail.com or call me at 561-549-9099.


Dr. Mann bust-shotDr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs

If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 866-634-2745 or email Dr. Mann at realmlabs123@gmail.com

Dr. Mann is the developer of the  NeuRemedy®line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs.  Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*

The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.*

NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*

For more information on NeuRemedy:
In the USA contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.

Leave a Reply

Your email address will not be published. Required fields are marked *